report updat estim price
target follow consid mix result
posit neg chanc catch
prgo ceo ir sever occas continu walk away
favor view new manag team grasp
challeng return higher growth
quick fix reiter commit make
pure-play consum compani eventu sell
spin gener busi rx pharma howev peer
valuat low may better keep gener
cash flow like progress thu far outlook
robust growth still dramat improv even though
compani better focus chang take time share
believ reflect enthusiasm chang yet
happen rais price target roll forward dcf
quarter rais target ebitda multipl
result updat revenu guidanc rang
account ranir acquisit
model revenu new estim versu
previou expect prgo adjust ep guidanc
estim adjust ep
versu previou expect note though
revenu increas due ranir acquisit adjust tax
rate higher reflect prgo guidanc
accur previous rate model
note prgo guidanc includ impact
potenti gener proair approv could provid upsid
cent per quarter could late event
interest hear manag
previou potenti target electron nicotin replac
therapi cbd product still attract given recent news
overal make progress acquisit ranir allow
nice setup go comp get easier
vs growth seen csca exclud one-
time item make tough get excit base busi
face uncertainti tax situat ir
assessments/penalti believ result larg
payment maintain market perform rate rais price
target
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
report non-gaap adjust ep exclud one-tim item
compani data secur llc estim reuter
million except per share valu
compani file factset secur llc estim
guidanc fargo secur estimatefactset consensusnet dsg oper tax share previou new
perrigo incom sc sc expens expens incom per specialti
price target
price target base dcf valuat includ discount rate termin
multipl integr larg part outlook carri substanti risk
risk includ turnaround brand consum healthcar busi weak rx
pharmaceut irish tax disput
believ share perform market evid emerg recent
turnaround durabl particularli relat eu busi gener busi tax
liabil recent under-perform
began packag gener home remedi year later one top
over-the-count over-the-counter consum good product compani market share privat label
store brand also among lead compani pharmaceut gener market
well activ pharmaceut ingredi api market
